Abstract: Abstract: Objective To evaluate the long- term prognostic capacity of the SYNTAX score Ⅱ(SxScore Ⅱ) and SYNTAX score (SxScore) in patients undergoing left main percutaneous coronary intervention (LM-PCI). Methods A total of 209 patients undergoing unprotected LM-PCI in the Cardiology Department of the Affiliated Hospital of PAP of Logistic College were prospectively collected. Follow up was carried out by telephone or outpatient or rehospitalization. The clinical endpoint focused on MACCE after PCI including composite death, nonfatal myocardial infarction, target vessel revascularization and stroke. The secondary endpoint included cardiac death and stent thrombosis. The SxScore and SxScore Ⅱ were retrospectively calculated according to results of coronary angiography and clinical features of patients. Patients were stratified according to tertiles of low (≤22), intermediate (23-32), and high (≥33). The clinical data were compared between three groups. The predictive ability of two scoring systems to MACCE after PCI was compared by COX regression evaluation. Results In 209 patients, 12 patients were lost to follow-up (5.7%), and the median follow-up was 30.2 months, 56 cases (28.4%) were observed to suffer from MACCE. The incidence rates of MACCE were 19.0%, 28.6% and 44.4% in SxScore low, intermediate and high groups respectively. The incidence rates of MACCE were 12.8%, 23.8% and 45.5% in SxScoreⅡlow, intermediate and high groups respectively. Single factor analysis showed that SxScore, SxScore Ⅱ, age, diabetes and left ventricular ejection fraction (LVEF) were the independent predictors of MACCE. Multivariate analysis showed that SxScore and SxScoreⅡwere still risk independent predictors for MACCE. Conclusion Both SxScore and SxScore Ⅱare independent risk predictors for MACCE in patients with unprotected left main coronary artery disease undergoing PCI treatment.

Key words: angioplasty, transluminal, percutaneous coronary, coronary artery disease, unprotected left main coronary artery, SxScore, SxScoreⅡ, major adverse cardiac and cerebrovasculur events